Anti Inflammatory News and Research

RSS

Advance your analysis of cannabis with Restek’s new Cannabidivarinic Acid standard

Cannabidivarinic Acid is a non-psychoactive cannabinoid reported to have anti-inflammatory properties.

From Restek Corporation 19 Jun 2020

Crystal structure of SARS-CoV-2 protease-inhibitor in complex with a Chinese herb Shikonin

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has been spreading rampantly over the whole world, infecting millions of people (over 8.45 million at last count), with over 452,000 deaths, as of June 19, 2020. It causes a broad spectrum of disease manifestations, from asymptomatic disease to severe or even fatal respiratory symptoms.

18 Jun 2020

Managing pain after sports medicine procedures without opioids

A Henry Ford Hospital study published in the Journal of Arthroscopic and Related Surgery, has found that patients who underwent knee surgery and other types of sports medicine procedures could manage their pain without opioids or a minimal dosage.

18 Jun 2020

Two clinical trials use low-dose X-rays to treat COVID-19 pneumonia

Previous studies have shown that low-dose, whole lung radiation in the form of X-rays can effectively treat severe pneumonia, with minimal side effects.

17 Jun 2020

New nanoparticle drug combination can help treat atherosclerosis

Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

17 Jun 2020

Early intensive treatment of rheumatoid arthritis offers an opportunity to manage fatigue

Disease-related, profound fatigue impairs the quality of life of many people with rheumatic and musculoskeletal diseases.

17 Jun 2020

Severity of COVID-19 linked to heparanase activity and heparan sulfate levels

Researchers at Radboud University Medical Center in the Netherlands reported an increase of heparanase activity and heparan sulfate levels in the plasma of patients with coronavirus disease (COVID-19), which was also associated with the severity of the condition – suggesting, in turn, potential treatment utility of low molecular weight heparins. The paper is currently available on the medRxiv* preprint server.

16 Jun 2020

Persistent DNA damage in the placenta can affect embryonic growth

Scientists at the Stowers Institute for Medical Research have shown that a dysfunctional placenta can play a previously unrecognized role during the earliest stages of development in mouse models of Cornelia de Lange syndrome.

16 Jun 2020

Life saving drug found for COVID-19 patients on ventilators

Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.

16 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Common cholesterol-lowering drug linked to improvement in gut microbiota

There is a clear link between improved gut microbiota and one of our most common cholesterol-lowering drug groups: statins.

15 Jun 2020

An inverse relationship between smoking and COVID-19

Researchers at the University of Washington and Stanford University School of Medicine have reported a significant inverse relationship between current smoking and coronavirus disease 2019 (COVID-19) mortality rates across forty countries.

15 Jun 2020

Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models

A study on the effects of hydroxychloroquinei n macaques infected with the SARS-CoV-2 virus, , used alone or in combination with azithromycin, have been pre-published on Research Square, after their submission to Nature.

12 Jun 2020

Type III interferons can increase risk of bacterial "superinfections" in the lung, research shows

Interferons and other cytokines produced by the immune system are important defenses against viral infections, but as we have seen in COVID-19, they can also contribute to damaging, potentially life-threatening lung inflammation.

12 Jun 2020

Antihypotensive agent for sepsis disrupts the immune system, increases susceptibility to infections

Patients who go into shock caused by sepsis (septic shock) are treated with the antihypotensive agent norepinephrine.

11 Jun 2020

Study shows safety of new cell therapy approaches for kidney transplant recipients

A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

10 Jun 2020

NIH-funded researchers to assess drugs prescribed to treat COVID-19 in children

Researchers funded by the National Institutes of Health have launched an effort to evaluate drugs prescribed to treat COVID-19 in infants, children and adolescents across the country. The study leverages an existing clinical trial that examines drugs that are prescribed off-label to children for a variety of medical conditions.

10 Jun 2020